BeyondSpring Inc. (NASDAQ: BYSI) announced new analyses from its DUBLIN-3 Phase 3 study showing that plinabulin combined with docetaxel improved ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE